Sign Up Today and Learn More About Retension Pharmaceuticals Stock
Invest in or calculate the value of your shares in Retension Pharmaceuticals or other pre-IPO companies through EquityZen's platform.
Retension Pharmaceuticals Stock
Retension Pharmaceuticals is a healthcare company.
About Retension Pharmaceuticals Stock
Founded
2023
Headquarters
Falls Church, VA, US
Industries
Software, Artificial Intelligence, Data and Analytics
Retension Pharmaceuticals Press Mentions
Stay in the know about the latest news on Retension Pharmaceuticals
Crystalline forms of 4-ethoxy-n-(2-methoxyethyl)-n-methyl-3-(5-methyl-4-oxo-7- …
patents • Mar 01, 2026
Retension Pharmaceuticals: $15 Million Raised For Developing Hypertension Drug
pulse2 • Aug 09, 2025
Retension Pharmaceuticals Scores $15M
vcnewsdaily • Aug 07, 2025
Retension Pharmaceuticals Secures $15M Series B Financing for Hypertension Treatment
venturecapital • Aug 07, 2025
Retension Pharmaceuticals Raises $15 Million In Series B
citybiz • Aug 07, 2025
Retension Pharmaceuticals Management
Leadership team at Retension Pharmaceuticals
President
Shoshana Shendelman
CEO and Co-Founder
Eric Keller
Join now and verify your accreditation status to gain access to:
- Retension Pharmaceuticals Current Valuation
- Retension Pharmaceuticals Stock Price
- Retension Pharmaceuticals Management
- Available deals in Retension Pharmaceuticals and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Retension Pharmaceuticals Cap Table and Funding History by Share Class and Liquidity Preferences
- Retension Pharmaceuticals Revenue and Financials
- Retension Pharmaceuticals Highlights
- Retension Pharmaceuticals Business Model
- Retension Pharmaceuticals Risk Factors
- Retension Pharmaceuticals Research Report from SACRA Research
Trading Retension Pharmaceuticals Stock
How to invest in Retension Pharmaceuticals stock?
Accredited investors can buy pre-IPO stock in companies like Retension Pharmaceuticals through EquityZen funds. These investments are made available by existing Retension Pharmaceuticals shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell Retension Pharmaceuticals stock?
Shareholders can sell their Retension Pharmaceuticals stock through EquityZen's private company marketplace. EquityZen's network includes over 440K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 52K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."